Safety and Efficacy of Oral NXC-736 in Adult Participants With Severe Alopecia Areata

• Status: Not yet recruiting
• Trial end date: 2025-06-30
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety and efficacy of NXC-736 monotherapy in participants with severe alopecia areata (AA).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: NEXTGEN Bioscience

Criteria

Inclusion Criteria:

• Men or women between ≥19 and ≤65 years of age at the time of informed consent

• Severe alopecia areata as assessed by a SALT score of ≥50 at Screening and Day 1/Baseline

• Current episode of hair loss for ≥6 months but <8 years

• Stable disease condition (no significant growth of hair) in the last 6 months as assessed by the Investigator

• Willing to keep the same hair style and color (eg, hair products, process, and timing for hair appointments) for the duration of the study

Exclusion Criteria:

• Participants with the following medical history confirmed during screening:

• ohter Types of alopecia other than alopecia areata (such as cicatricial/scarring alopecia [including central centrifugal cicatricial alopecia], traction alopecia, androgenic alopecia, telogen effluvium, etc.)

• Active scalp inflammation, scalp infection, scalp psoriasis, or any other scalp condition that may interfere with the SALT assessment

• Previous use of Janus kinase (JAK) inhibitor (oral or topical), including participation in clinical studies of JAK inhibitors